68Ga-FAPI PET/CT scans to look for heart scarring in people with heart failure
Tests a PET/CT scan that looks for heart scarring in adults with heart failure.
Key facts
- Who runs it
- University of Coimbra
- Where
- Coimbra, PortugalSee the site
- Trial code
- Registry title
- ⁶⁸Ga-FAPI PET/CT for Cardiac Fibrosis in Heart Failure
- Status
- Recruiting
- People taking part
- 30 people, planned
- Started
- 17 Nov 2025
- Expected to end
- 31 Dec 2028
- Type of study
- Observational
- Treatments tested
- 68Ga-FAPI PET/CT
- Record updated
- 29 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with heart failure caused by dilated cardiomyopathy with weak pumping, or by hypertrophic cardiomyopathy with normal pumping. It uses a special PET/CT scan to look at heart scarring.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Signs and symptoms of heart failure. Either normal pumping (LVEF ≥50%) with signs of stiff heart or hypertrophic cardiomyopathy, or weak pumping (LVEF ≤40%) with dilated cardiomyopathy.
- Biomarker or test result
- For the hypertrophic group, a genetic diagnosis due to a sarcomeric gene mutation is listed. Elevated natriuretic peptides may be used as evidence of heart changes.
Main reasons for not taking part
- Pregnant or breastfeeding women
- Kidney disease with glomerular filtration rate <30 mL/min/1.73m²
- Cancer within the past 5 years
- Implanted cardiac electrical device
- Hospitalized for heart failure in the last 30 days
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- ≥ 18 years old
- Signs and symptoms of heart failure (HF)
- [Preserved left ventricular ejection fraction (LVEF) (≥50%) and Evidence of structural/functional abnormality consistent with diastolic dysfunction/increased ventricular filling pressures, including elevated natriuretic peptides and Imaging diagnosis of hypertrophic cardiomyopathy and Genetic diagnosis of hypertrophic cardiomyopathy due to sarcomeric gene mutation] OR [Reduced LVEF (≤40%) and Imaging diagnosis of dilated cardiomyopathy: left ventricular end-diastolic diameter >58 mm in men and >52 mm in women, and left ventricular volume ≥75 mL/m² in men and ≥62 mL/m² in women, not explained solely by loading conditions]
- Recent transthoracic echocardiogram (< 3 months)
- Recent cardiac magnetic resonance imaging (< 3 months)
- Normal coronary angiogram or computed tomography coronary angiography within 6 months of enrolment
Who cannot take part
- Chronic kidney disease with glomerular filtration rate <30 mL/min/1.73m²
- Malignant neoplasms within the past 5 years
- Significant primary valvular disease
- Significant atherosclerotic coronary artery disease
- Grade 2 or 3 arterial hypertension
- Presence of an implanted cardiac electrical device
- Recent hospitalization for heart failure (<30 days)
- Inability to provide informed consent
- Inability to tolerate the supine position
- Hemodynamic instability
- Claustrophobia
- Pregnant or breastfeeding women
Where in Portugal
- Faculdade de Medicina da Universidade de CoimbraCoimbra, PortugalContact: João Borges Rosa, MDTaking people
About the trial
What the trial wants to find out
Heart failure (HF) is a clinical syndrome with increasing incidence and prevalence, associated with high morbidity, mortality, and economic impact, despite therapeutic advances.
Read full original descriptionShow less
Myocardial fibrosis is a common feature across different pathophysiological processes and plays a key role in HF development, with growing research interest specifically in non-ischemic dilated cardiomyopathy (HFrEF phenotype) and hypertrophic cardiomyopathy (HFpEF phenotype). Given its potential reversibility with certain drugs, fibrosis is an attractive therapeutic target, requiring non-invasive methods to monitor fibrogenesis and treatment efficacy.
Cardiac magnetic resonance imaging (CMR) is the gold standard for detecting fibrosis but cannot distinguish between active and inactive fibrosis or detect early stages, limitations that may be addressed by gallium-68-labeled fibroblast activation protein inhibitor positron emission tomography/computed tomography (68Ga-FAPI PET/CT).
This single-center, prospective, observational pilot study aims primarily to assess myocardial fibrosis in patients with HFrEF (non-ischemic dilated cardiomyopathy) and a subtype of HFpEF (hypertrophic cardiomyopathy) using 68Ga-FAPI PET/CT compared to CMR.
Secondary objectives include developing 68Ga-FAPI uptake assessment methodologies for future anti-fibrotic therapy studies and correlating fibrosis with serum cardiac biomarkers and cardiovascular events.
The group in the trial
- patients with HFrEF and HFpEF
patients with HFrEF (non-ischemic dilated cardiomyopathy) and HFpEF (hypertrophic cardiomyopathy)
Treatment: 68Ga-FAPI PET/CT
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Myocardial Fibrosis in Heart Failure: A Pilot Study With 68Ga-FAPI PET/CT
- Plain-language title
- 68Ga-FAPI PET/CT scans to look for heart scarring in people with heart failureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 29 December 2025